Recently, Hengguang Co., Ltd. (stock code: 301118) announced that a shareholder holding more than 5% of the company’s shares plans to reduce its stake by up to 2.99% of the total share capital through centralized bidding or block trading. The proposed reduction will take place within six months starting 15 trading days after the announcement, with no more than 1% of total shares sold via centralized bidding in any consecutive 90-day period.Hengguang specializes in the research, development, production, and sale of fine chemical products, which are widely used in pharmaceuticals, agrochemicals, and dyes. The selling shareholder is neither the controlling shareholder nor the actual controller of the company, so this reduction will not result in a change of control or significantly impact the company’s governance or ongoing operations.Market analysts note that while such share sales may exert short-term downward pressure on the stock price, if the motivation is personal liquidity needs rather than pessimism about the company’s outlook, the long-term fundamentals remain largely unaffected. Investors should focus on the company’s future earnings, industry trends, and broader market conditions when assessing its investment value.Notably, the 2.99% cap appears strategically set just below the 3% threshold that would trigger stricter disclosure requirements. Overall, this move represents normal market behavior and warrants attention—but not undue concern—from investors.
近日，恒光股份（股票代码：301118）发布公告称，公司持股5%以上股东拟通过集中竞价或大宗交易方式减持不超过公司总股本2.99%的股份。本次减持计划自公告披露之日起15个交易日之后的六个月内实施，且在任意连续90日内，通过集中竞价交易方式减持比例不超过公司总股本的1%。恒光股份主要从事精细化工产品的研发、生产和销售，产品广泛应用于医药、农药、染料等领域。此次减持的股东并非公司控股股东或实际控制人，因此减持行为不会导致公司控制权发生变更，也不会对公司治理结构及持续经营产生重大影响。市场分析人士指出，股东减持虽可能短期内对股价造成一定压力，但若减持出于个人资金需求而非对公司前景看淡，则对中长期基本面影响有限。投资者应关注公司后续业绩表现、行业景气度及整体市场环境，理性判断投资价值。值得注意的是，2.99%的减持比例接近3%的披露门槛，此举或意在避免触发更严格的信息披露要求。总体来看，本次减持属正常市场行为，投资者无需过度解读，但仍需保持关注。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/14539.html